Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
In Australia, all newborns born in New South Wales (NSW) and the Australia Capital Territory (ACT) have been offered screening for rare congenital conditions through the NSW Newborn Screening Programme since 1964. Following the development of the Australian Newborn Bloodspot Screening National Policy Framework, screening for congenital adrenal hyperplasia (CAH) was included in May 2018. As part of the assessment for addition of CAH, the national working group recommended a two-tier screening protocol determining 17α-hydroxyprogesterone (17OHP) concentration by immunoassay followed by steroid profile. A total of 202,960 newborns were screened from the 1 May 2018 to the 30 April 2020. A threshold level of 17OHP from first tier immunoassay over 22 nmol/L and/or top 2% of the daily assay was further tested using liquid chromatography tandem mass spectrometry (LC-MS/MS) steroid profiling for 17OHP (MS17OHP), androstenedione (A4) and cortisol. Samples with a ratio of (MS17OHP + A4)/cortisol > 2 and MS17OHP > 200 nmol/L were considered as presumptive positive. These newborns were referred for clinical review with a request for diagnostic testing and a confirmatory repeat dried blood spot (DBS). There were 10 newborns diagnosed with CAH, (9 newborns with salt wasting CAH). So far, no known false negatives have been notified, and the protocol has a sensitivity of 100%, specificity of 99.9% and a positive predictive value of 71.4%. All confirmed cases commenced treatment by day 11, with none reported as having an adrenal crisis by the start of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and both heel stick blood samples (266) and urine samples (267,268) can also be analyzed by mass spectrometric methods.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [268]
The cited source says what the claim attributes to it.
In the citing paper
“Steroids can be measured in blood, urine (268,305), saliva (388) and dried filter-paper blood samples (389,390) and fluctuate with both the circadian rhythm and the timing of glucocorticoid intake (298,391-393).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [268]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Usually, a spot urine sample is sufficient for diagnosing an adrenal enzyme defect (268,294,295).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [268]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care
Lee, P. A., Nordenström, A., Houk, C. P., Ahmed, S. F., Auchus, R., Baratz, A., Baratz Dalke, K., Liao, L.-M., Lin-Su, K., Looijenga 3rd, L. H. J., et al. (2016) · Hormone Research in Paediatrics · doi:10.1159/000442975 · Cited by 1,273
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 7×
“Following diagnostic sample results and clinical review, 10 were proven to have CAH with 9 SWCAH and 1 newborn classified SVCAH.”
InfluentialCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669 · cited 1×
“SWCAH can present with a life-threatening adrenal crisis within the first two weeks of life [51].”
BackgroundPang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392 · cited 1×
“Reported observed incidence is highest in Yupik Eskimos from Southern Alaska at 1:282 [9].”
BackgroundPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
PANG, S., HOTCHKISS, J., DRASH, A. L., LEVINE, L. S., & NEW, M. I. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-5-1003 · Cited by 293
Neonatal screening for congenital adrenal hyperplasia
White, P. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.148 · Cited by 240
Wudy, S. A., Schuler, G., Sánchez-Guijo, A., & Hartmann, M. F. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.09.003 · Cited by 236
Lacey, J. M., Minutti, C. Z., Magera, M. J., Tauscher, A. L., Casetta, B., McCann, M., Lymp, J., Hahn, S. H., Rinaldo, P., & Matern, D. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.027193 · Cited by 216 · cited 1×
“Early clinical symptoms can be non-specific such as poor feeding, vomiting, diarrhoea and sepsis, which can lead to erroneous diagnoses [24].”
BackgroundJanzen, N., Peter, M., Sander, S., Steuerwald, U., Terhardt, M., Holtkamp, U., & Sander, J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2890 · Cited by 211 · cited 1×
“, 17OHP + 21-deoxycortisol/cortisol) has been shown to be specific for 21 hydroxylase deficiency [49].”
BackgroundPang, S., Wallace, M. A., Hofman, L. F., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · PEDIATRICS · doi:10.1542/peds.81.6.866 · Cited by 191
Wilcken, B. M., & Wiley, V. C. (2008) · Pathology · doi:10.1080/00313020701813743 · Cited by 190
Oxford Handbook of Endocrinology and Diabetes
(2014) · doi:10.1093/med/9780199644438.001.0001 · Cited by 177
Pang, S., Clark, A., Neto, E. C., Giugliani, R., Dean, H., Winter, J., Dhondt, J.-L., Farriaux, J. P., Graters, A., Cacciari, E., et al. (1993) · Screening · doi:10.1016/0925-6164(93)90024-d · Cited by 161 · cited 1×
“Newborn screening for CAH is aimed at identifying newborns with SWCAH promptly to prevent a life threatening adrenal crisis, thus reducing morbidity and mortality in affected individuals [23].”
BackgroundCongenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2010.10.001 · Cited by 159
A Pilot Newborn Screening for Congenital Adrenal Hyperplasia in Alaska*
PANG, S., MURPHEY, W., LEVINE, L. S., SPENCE, D. A., LEON, A., LAFRANCHI, S., SURVE, A. S., & NEW, M. I. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-3-413 · Cited by 157
Newborn screening in North America
Therrell, B. L., & Adams, J. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0690-z · Cited by 141
Gidlöf, S., Wedell, A., Guthenberg, C., von Döbeln, U., & Nordenström, A. (2014) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2013.5321 · Cited by 119 · cited 1×
“Although gestational age stratification of 17OHP concentration was shown to give higher specificity, birth weight stratification has been more widely used [22,41,42].”
Methodvan der Kamp, H. J., Oudshoorn, C. G. M., Elvers, B. H., van Baarle, M., Otten, B. J., Wit, J. M., & Verkerk, P. H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2136 · Cited by 114 · cited 1×
“Although gestational age stratification of 17OHP concentration was shown to give higher specificity, birth weight stratification has been more widely used [22,41,42].”
MethodOxford Textbook of Endocrinology and Diabetes
(2011) · doi:10.1093/med/9780199235292.001.1 · Cited by 112
Genetics of Congenital Adrenal Hyperplasia
Hannah-Shmouni, F., Chen, W., & Merke, D. P. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.008 · Cited by 97
The Complexities in Genotyping of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency
Pignatelli, D., Carvalho, B. L., Palmeiro, A., Barros, A., Guerreiro, S. G., & Macut, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00432 · Cited by 95 · cited 1×
“Further, current molecular assays require at least 2 days to provide results, therefore the length of time to generate results is a deterrent for newborn screening [36,52].”
BackgroundNewborn Screening for Congenital Adrenal Hyperplasia inthe Netherlands
Van der Kamp, H. J., Noordam, K., Elvers, B., Van Baarle, M., Otten, B. J., & Verkerk, P. H. (2001) · PEDIATRICS · doi:10.1542/peds.108.6.1320 · Cited by 86
The next 150 years of congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.013 · Cited by 70 · cited 1×
“There remain reservations, as CAH can be detected through clinical assessment and there are noted to be high false-positive rates generated from immunoassay in low birth weight premature infants [22,32,33].”
BackgroundSteroid 21 Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Nimkarn, S., Lin‐Su, K., & New, M. I. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.012 · Cited by 67 · cited 1×
“SWCAH, accounting for approximately 75% of classical CAH presentation, is the most severe form of CAH [7,8].”
BackgroundNewborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013
Heather, N. L., Seneviratne, S. N., Webster, D., Derraik, J. G. B., Jefferies, C., Carll, J., Jiang, Y., Cutfield, W. S., & Hofman, P. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3168 · Cited by 65
Optimizing Newborn Screening for Congenital Adrenal Hyperplasia
White, P. C. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.02.008 · Cited by 56 · cited 1×
“There remain reservations, as CAH can be detected through clinical assessment and there are noted to be high false-positive rates generated from immunoassay in low birth weight premature infants [22,32,33].”
BackgroundScreening for neonatal endocrinopathies: rationale, methods and results
Vliet, G. V., & Czernichow, P. (2003) · Seminars in Neonatology · doi:10.1016/s1084-2756(03)00115-5 · Cited by 55 · cited 1×
“It has also been suggested that newborn screening for CAH only benefits male newborns, as females can be clinically detected due to virilisation [35].”
BackgroundHayashi, G. Y., Carvalho, D. F., de Miranda, M. C., Faure, C., Vallejos, C., Brito, V. N., Rodrigues, A. D. S., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13292 · Cited by 52
Determination of a steroid profile in heel prick blood using LC-MS/MS
Boelen, A., Ruiter, A. F., Claahsen-van der Grinten, H. L., Endert, E., & Ackermans, M. T. (2016) · Bioanalysis · doi:10.4155/bio.16.6 · Cited by 49
Tsuji, A., Konishi, K., Hasegawa, S., Anazawa, A., Onishi, T., Ono, M., Morio, T., Kitagawa, T., & Kashimada, K. (2015) · BMC Pediatrics · doi:10.1186/s12887-015-0529-y · Cited by 48
Congenital adrenal hyperplasia and the second newborn screen
Chan, C. L., McFann, K., Taylor, L., Wright, D., Zeitler, P. S., & Barker, J. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.01.002 · Cited by 46
Fifty years of newborn screening
Wilcken, B. M., & Wiley, V. C. (2015) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12817 · Cited by 42
Gleeson, H. K., Wiley, V., Wilcken, B., Elliott, E., Cowell, C., Thonsett, M., Byrne, G., & Ambler, G. (2008) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2008.01383.x · Cited by 39 · cited 2×
“Similarly, in NSW a two-year pilot program from 1st October 1995 to 30th September 1997 [29] showed that despite stratified action limits for low birth weight newborns there were 6% of infants <2 kg birth weight requiring further sample collection compared to 0.”
BackgroundComparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants
Sarafoglou, K., Gaviglio, A., Hietala, A., Frogner, G., Banks, K., McCann, M., & Thomas, W. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.01.038 · Cited by 38
Newborn screening for congenital adrenal hyperplasia in New York State
Pearce, M., DeMartino, L., McMahon, R., Hamel, R., Maloney, B., Stansfield, D.-M., McGrath, E. C., Occhionero, A., Gearhart, A., Caggana, M., et al. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.02.005 · Cited by 36
Kopacek, C., de Castro, S. M., Prado, M. J., da Silva, C. M. D., Beltrão, L. A., & Spritzer, P. M. (2017) · BMC Pediatrics · doi:10.1186/s12887-016-0772-x · Cited by 36
Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia
Hicks, R. A., Yee, J. K., Mao, C. S., Graham, S., Kharrazi, M., Lorey, F., & Lee, W. P. (2014) · Metabolomics · doi:10.1007/s11306-013-0558-1 · Cited by 35
Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
Güran, T., Tezel, B., Gürbüz, F., Eklioğlu, B. S., Hatipoğlu, N., Kara, C., Aydın, M., Şimşek, E., Çizmecioğlu, F. M., Özön, A., et al. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2018.2018.0117 · Cited by 32
Evaluation of the Dutch neonatal screening for congenital adrenal hyperplasia
van der Linde, A. A. A., Schönbeck, Y., van der Kamp, H. J., van den Akker, E. L. T., van Albada, M. E., Boelen, A., Finken, M. J. J., Hannema, S. E., Hoorweg-Nijman, G., Odink, R. J., et al. (2019) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-315972 · Cited by 32
Choi, R., Park, H.-D., Oh, H. J., Lee, K., Song, J., & Lee, S.-Y. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.3.263 · Cited by 29
Hird, B. E., Tetlow, L., Tobi, S., Patel, L., & Clayton, P. E. (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304473 · Cited by 25 · cited 1×
“A study from the United Kingdom argued that screening for CAH has no impact on the morbidity and mortality of patients with CAH and therefore does not include CAH in its screening program [34].”
BackgroundBialk, E. R., Lasarev, M. R., & Held, P. K. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5030033 · Cited by 25
Turan, I., Tastan, M., Boga, D. D., Gurbuz, F., Kotan, L. D., Tuli, A., & Yüksel, B. (2020) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2019.103782 · Cited by 25
Rossi, C., Calton, L. J., Brown, H. A., Gillingwater, S., Wallace, A. M., Petrucci, F., Ciavardelli, D., Urbani, A., Sacchetta, P., & Morris, M. R. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.109 · Cited by 24
Newborn Screening for Congenital Adrenal Hyperplasia in India: What Do We Need to Watch Out for?
Kumar, R. K., Das, H., & Kini, P. (2015) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-015-0712-y · Cited by 22
Votava, F., Novotná, D., Kračmar, P., Vinohradská, H., Stahlova-Hrabincova, E., Vrzalová, Z., Neumann, D., Malíková, J., Lebl, J., & Matern, D. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-011-1656-6 · Cited by 19
Tieh, P. Y., Yee, J. K., Hicks, R. A., Mao, C. S., & Lee, W.-N. (2017) · Journal of Perinatology · doi:10.1038/jp.2016.223 · Cited by 19
Congenital adrenal hyperplasia
Simpson, H., & Hughes, I. A. (2017) · Medicine · doi:10.1016/j.mpmed.2017.05.012 · Cited by 18
Sarafoglou, K., Lorentz, C. P., Otten, N., Oetting, W. S., & Grebe, S. K. G. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01694.x · Cited by 16 · cited 2×
“Variant analysis has been reported to be able to further discriminate SVCAH from SWCAH [53]; however, so far the literature suggests that variant analysis has only been used as an adjunct for screening [36].”
BackgroundResultThe case for newborn screening for congenital adrenal hyperplasia in Australia
Warne, G. L., Armstrong, K. L., Faunce, T., Wilcken, B. M., Boneh, A., Geelhoed, E. A., & Craig, M. E. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03432.x · Cited by 12 · cited 1×
“In Australia, the inclusion of newborn screening for CAH was proposed to each state government at various times over the intervening years by the Australasian Pediatric Endocrine Group and the Human Genetic Society of Australasia (HGSA) [30].”
BackgroundA pilot study on newborn screening for congenital adrenal hyperplasia in Beijing
Gong, L.-F., Gao, X., Yang, N., Zhao, J.-Q., Yang, H.-H., & Kong, Y.-Y. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0342 · Cited by 11
Dörr, H. G., Odenwald, B., & Nennstiel, U. (2015) · International Journal of Neonatal Screening · doi:10.3390/ijns1010036 · Cited by 8
Cited by
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Therrell, B. L., Padilla, C. D., Borrajo, G. J. C., Khneisser, I., Schielen, P. C. J. I., Knight‐Madden, J., Malherbe, H. L., & Kase, M. (2024) · International Journal of Neonatal Screening · doi:10.3390/ijns10020038 · Cited by 203
Current and Novel Treatment Strategies in Children with Congenital Adrenal Hyperplasia
Nordenström, A., Falhammar, H., & Lajić, S. (2022) · Hormone Research in Paediatrics · doi:10.1159/000522260 · Cited by 41
Neonatal Screening for Congenital Adrenal Hyperplasia in Denmark: 10 Years of Experience
Lind‐Holst, M., Bækvad‐Hansen, M., Berglund, A., Cohen, A. S., Melgaard, L., Skogstrand, K., Dunø, M., Main, K. M., HOUGAARD, D. M., Gravholt, C. H., et al. (2022) · Hormone Research in Paediatrics · doi:10.1159/000522230 · Cited by 24
Grosse, S. D., & Vliet, G. V. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6040082 · Cited by 22
Metadata
- Authors
- Lai, F., Srinivasan, S., & Wiley, V.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Lai, Fei
- ORCID
- Srinivasan, Shubha
- Venue
- International Journal of Neonatal Screening
- Publisher
- MDPI AG
- Published
- 2020-08-12
- Volume
- 6
- Issue
- 3
- Pages
- 63
- ISSN
- 2409-515X (ISSN-L)
- PMC
- PMC7569785
- OpenAlex
- W3048462612
- Cited by
- 32
- References
- 57
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Neonatal Screening (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- congenital adrenal hyperplasia, newborn screening, 17-hydroxyprogesterone, dried blood spots, steroid profile, salt-wasting CAH, screening sensitivity and specificity, positive predictive value, adrenal crisis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.